Drug regulators and trial designs should assess benefits that actually matter to people with cancer, says Ajay Aggarwal.
Forfeiting our commons
The Lancet’s Series on Maternal and Child Undernutrition
President Obama's grand climate plan does not add up
Climate change can no longer be ignored
NGO demands withdrawal of Niyamgiri gram sabha notificatio